Cardiovascular Disease and Diabetic Kidney Disease

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Summary: Diabetic kidney disease commonly is associated with an increased risk of cardiovascular disease. There are traditional common risk factors for both conditions including hypertension and poor glycemic control. However, it is likely that there are other pathophysiological mechanisms that explain the clinical phenomenon of increased cardiovascular disease in diabetic patients with chronic kidney and vice versa. Current management of both conditions includes aggressive glucose and blood pressure control. The protective role of treating dyslipidemia has been shown for cardiovascular disease, but the results for renal disease are not as clear. The advent of new classes of glucose-lowering agents such as sodium glucose co-transporter2 inhibitors and glucagon-like peptide-1 agonists has resulted in impressive effects on both cardiovascular and renal disease in diabetes. However, how these drugs act independently of glucose lowering to confer both kidney and cardiovascular protection has not been fully elucidated. Nevertheless, these new treatments provide optimism for reducing both microvascular and macrovascular complications in diabetes, which represent the major causes of morbidity and premature mortality in this condition.

Original languageEnglish
Pages (from-to)217-232
Number of pages16
JournalSeminars in Nephrology
Volume38
Issue number3
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • Cardiovascular disease
  • diabetes
  • diabetic nephropathy
  • hyperlipidemia
  • hypertension
  • treatments

Cite this

@article{bfeb32828c534521bad736e70ea28d27,
title = "Cardiovascular Disease and Diabetic Kidney Disease",
abstract = "Summary: Diabetic kidney disease commonly is associated with an increased risk of cardiovascular disease. There are traditional common risk factors for both conditions including hypertension and poor glycemic control. However, it is likely that there are other pathophysiological mechanisms that explain the clinical phenomenon of increased cardiovascular disease in diabetic patients with chronic kidney and vice versa. Current management of both conditions includes aggressive glucose and blood pressure control. The protective role of treating dyslipidemia has been shown for cardiovascular disease, but the results for renal disease are not as clear. The advent of new classes of glucose-lowering agents such as sodium glucose co-transporter2 inhibitors and glucagon-like peptide-1 agonists has resulted in impressive effects on both cardiovascular and renal disease in diabetes. However, how these drugs act independently of glucose lowering to confer both kidney and cardiovascular protection has not been fully elucidated. Nevertheless, these new treatments provide optimism for reducing both microvascular and macrovascular complications in diabetes, which represent the major causes of morbidity and premature mortality in this condition.",
keywords = "Cardiovascular disease, diabetes, diabetic nephropathy, hyperlipidemia, hypertension, treatments",
author = "Muhammad Maqbool and Cooper, {Mark E.} and Jandeleit-Dahm, {Karin A.M.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.semnephrol.2018.02.003",
language = "English",
volume = "38",
pages = "217--232",
journal = "Seminars in Nephrology",
issn = "0270-9295",
publisher = "Elsevier",
number = "3",

}

Cardiovascular Disease and Diabetic Kidney Disease. / Maqbool, Muhammad; Cooper, Mark E.; Jandeleit-Dahm, Karin A.M.

In: Seminars in Nephrology, Vol. 38, No. 3, 01.05.2018, p. 217-232.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Cardiovascular Disease and Diabetic Kidney Disease

AU - Maqbool, Muhammad

AU - Cooper, Mark E.

AU - Jandeleit-Dahm, Karin A.M.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Summary: Diabetic kidney disease commonly is associated with an increased risk of cardiovascular disease. There are traditional common risk factors for both conditions including hypertension and poor glycemic control. However, it is likely that there are other pathophysiological mechanisms that explain the clinical phenomenon of increased cardiovascular disease in diabetic patients with chronic kidney and vice versa. Current management of both conditions includes aggressive glucose and blood pressure control. The protective role of treating dyslipidemia has been shown for cardiovascular disease, but the results for renal disease are not as clear. The advent of new classes of glucose-lowering agents such as sodium glucose co-transporter2 inhibitors and glucagon-like peptide-1 agonists has resulted in impressive effects on both cardiovascular and renal disease in diabetes. However, how these drugs act independently of glucose lowering to confer both kidney and cardiovascular protection has not been fully elucidated. Nevertheless, these new treatments provide optimism for reducing both microvascular and macrovascular complications in diabetes, which represent the major causes of morbidity and premature mortality in this condition.

AB - Summary: Diabetic kidney disease commonly is associated with an increased risk of cardiovascular disease. There are traditional common risk factors for both conditions including hypertension and poor glycemic control. However, it is likely that there are other pathophysiological mechanisms that explain the clinical phenomenon of increased cardiovascular disease in diabetic patients with chronic kidney and vice versa. Current management of both conditions includes aggressive glucose and blood pressure control. The protective role of treating dyslipidemia has been shown for cardiovascular disease, but the results for renal disease are not as clear. The advent of new classes of glucose-lowering agents such as sodium glucose co-transporter2 inhibitors and glucagon-like peptide-1 agonists has resulted in impressive effects on both cardiovascular and renal disease in diabetes. However, how these drugs act independently of glucose lowering to confer both kidney and cardiovascular protection has not been fully elucidated. Nevertheless, these new treatments provide optimism for reducing both microvascular and macrovascular complications in diabetes, which represent the major causes of morbidity and premature mortality in this condition.

KW - Cardiovascular disease

KW - diabetes

KW - diabetic nephropathy

KW - hyperlipidemia

KW - hypertension

KW - treatments

UR - http://www.scopus.com/inward/record.url?scp=85044933666&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2018.02.003

DO - 10.1016/j.semnephrol.2018.02.003

M3 - Review Article

VL - 38

SP - 217

EP - 232

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 3

ER -